|Bid||19.96 x 800|
|Ask||21.54 x 1000|
|Day's Range||19.25 - 21.17|
|52 Week Range||13.40 - 29.51|
|Beta (5Y Monthly)||1.87|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||0.20 (0.96%)|
|Ex-Dividend Date||Dec 14, 2023|
|1y Target Est||N/A|
Shares of Paramount Global (NASDAQ: PARA) (NASDAQ: PARA.A) closed up 12% on Friday after Puck News reported that the entertainment conglomerate is the subject of takeover interest from Skydance Media and RedBird Capital Partners. Citing three sources familiar with the situation, the media outlet said that Skydance and RedBird are considering indirectly taking control of Paramount -- by acquiring media company National Amusements, which currently owns around 77% of Paramount's Class A voting shares.
The US Food and Drug Administration approved two therapies for the treatment of sickle cell disease. One of the treatments, Casgevy, uses CRISPR gene editing. The treatment’s developers, CRISPR Therapeutics (CRSP) and Vertex Pharmaceuticals (VRTX), are both trending on Yahoo Finance. Lululemon shares are soaring on its better-than-expected third-quarter results. Other trending tickers on Yahoo Finance include Paramount Global (PARA), RH (RH), and Broadcom (AVGO).Top guests on Yahoo Finance Live today include:3:05 p.m. ET - Reshma Kewalramani, CEO of Vertex Pharmaceuticals3:20 p.m. ET - Julia Pollak, ZipRecruiter Chief Economist3:30 p.m. ET - Jay Woods, Freedom Capital Markets Chief Global Strategist3:45 p.m. ET - Jason Kupferberg, Bank of America Senior Equity Research Analyst4:05 p.m. ET - Stephen Gengaro, Stifel Managing Director
Paramount stock surged Friday as reports continued to swirl regarding potential M&A deals for the media conglomerate.